Concert Pharma (CNCE) Reports Clinical Hold on CTP-543 Phase 2A Trial

May 17, 2017 7:32 AM

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found